When the Covid-19 pandemic first hit, many patients took what they thought would be a temporary break from preventive care visits to the doctor. However, more than two years later, people still aren’t coming in for their annual physicals and screenings at pre-pandemic levels. And with staff shortages, practices are being overwhelmed by even the lower numbers of patients who are coming in. 

According to the Journal of the National Cancer Institute, this is all leading to “substantial delays in both diagnoses and treatment “services” for patients with cancer.”¹ When it comes to cancer, timing is everything. The sooner a provider can diagnose a patient, the sooner they can begin providing potentially life-saving treatment. 

MyRisk is more than just a genetic test. Our personalized care plans provide expert guidance that go beyond positive or negative results, and produce a comprehensive assessment of your patients’ risk for hereditary cancer. This means you can better manage each patient’s risk for hereditary cancer in even more personalized ways – especially for those who’ve missed screenings over the past two years or delayed a diagnosis. 

With Myriad Genetics, both your patients and your practice will have support throughout the entire journey even during tough times and staff shortages. We have a human support team that’s readily available, the MyRisk Management Tool that makes results easy-to-understand, and Myriad Complete^TM that helps you navigate genetic testing with confidence.  

* Myriad Internal Data based on OBGYN and Primary Care Settings, Sept 2019 

1. Yabroff KR, Wu XC, Negoita S, et al. Association of the COVID-19 pandemic with patterns of statewide cancer services. J Natl Cancer Inst. Published online, June 28, 2021. doi:10.1093/jnci/djab122 

2. Retrieved from https://www.preventcancer.org/2021/08/a-year-into-covidamericans-are-getting-cancer-screenings-back-on-the-books/